Quince Therapeutics (NASDAQ:QNCX) Research Coverage Started at Rodman & Renshaw

Rodman & Renshaw assumed coverage on shares of Quince Therapeutics (NASDAQ:QNCX) in a report issued on Tuesday, Benzinga reports. The firm issued a buy rating and a $11.00 price objective on the stock.

Separately, EF Hutton Acquisition Co. I raised Quince Therapeutics to a “strong-buy” rating in a report on Tuesday, October 22nd.

Quince Therapeutics Stock Performance

NASDAQ QNCX opened at $1.62 on Tuesday. The company has a fifty day moving average price of $0.81 and a 200-day moving average price of $0.81. The firm has a market cap of $70.11 million, a price-to-earnings ratio of -1.29 and a beta of 0.86. The company has a debt-to-equity ratio of 0.29, a current ratio of 6.15 and a quick ratio of 6.15. Quince Therapeutics has a 1 year low of $0.51 and a 1 year high of $1.79.

Quince Therapeutics (NASDAQ:QNCX) last issued its quarterly earnings data on Tuesday, August 13th. The company reported ($0.18) earnings per share (EPS) for the quarter.

Insider Buying and Selling

In related news, President Charles S. Ryan acquired 48,387 shares of the firm’s stock in a transaction that occurred on Tuesday, August 20th. The stock was acquired at an average price of $0.65 per share, for a total transaction of $31,451.55. Following the completion of the acquisition, the president now owns 122,461 shares of the company’s stock, valued at approximately $79,599.65. This represents a 0.00 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In related news, President Charles S. Ryan bought 48,387 shares of Quince Therapeutics stock in a transaction dated Tuesday, August 20th. The stock was purchased at an average cost of $0.65 per share, with a total value of $31,451.55. Following the transaction, the president now directly owns 122,461 shares of the company’s stock, valued at approximately $79,599.65. The trade was a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Dirk Thye purchased 77,500 shares of the firm’s stock in a transaction dated Thursday, August 29th. The shares were bought at an average price of $0.69 per share, with a total value of $53,475.00. Following the purchase, the chief executive officer now owns 766,941 shares in the company, valued at $529,189.29. The trade was a 0.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last ninety days, insiders have purchased 158,887 shares of company stock valued at $105,609. 16.80% of the stock is owned by insiders.

About Quince Therapeutics

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.